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Background:  Innate immune (inflammatory) cells are activated early after allograft transplant and are active long term, inducing transplant 
vasculopathy, a leading cause of late transplant loss. Treatment of TV remains limited and there is a need for treatments to prevent 
transplant loss. The connective tissue matrix, specifically glycosaminoglycans (GAGs) in the endothelial glycocalyx, induce inflammatory 
cell activation through chemokine binding to form a signal array to attract monocytes and T cells. Recent studies predict a GAG blueprint 
that directs chemokine mediated cell migration.
methods:  We investigated early chemokine: GAG interactions after renal allograft transplantation using heparin sulfate HS- GAG deficient 
(KO) donor mice and a viral chemokine modulating protein (CMP) that blocks chemokine: GAG interactions, M-T7, that blocks C, CC and 
CXC chemokine: GAG interactions. Methods - 96 mice had C57Bl/6 (B6) to BALB/c renal allograft transplants; 48 had WT B6 transplant 
and 48 had Ndst1 HS-GAG KO in endothelial cells and myeloid precursors. Mice were treated for 10 days with either M-T7 or one of three 
point mutations (100ng/gm) with differing inhibitory actions for chemokine: GAG interactions, but no immunosuppressant.
results: Ndst1 HS-GAG KO in donor organs significantly reduced overall acute rejection by histology score (P < 0.0001). M-T7 also 
significantly reduced rejection and vasculitis in B6 allografts (P < 0.0001), but lost activity in Ndst1 KO allografts. Treatment with M-T7 Point 
mutations, E209I and R171E retained activity but R171E was inactive in Ndst1KO; F137D was inactive. CD3 + T cells were significantly 
reduced (P < 0.0001) in Ndst1 KO donor grafts and after M-T7 treatment in WT B6 transplants. PCR array analysis of HS GAG KO 
transplants and in B6 transplants with M-T7 treatment demonstrated significant reductions in inflammatory cytokines, chemokines and 
apoptotic pathways.
conclusion:   These studies indicate a major role for donor organ chemokine: GAG interaction in chronic allograft rejection and vascular 
disease, providing a wide range of new potential therapeutic options targeting donor allograft HS-GAG: chemokine interactions.
